Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10557020 | 1.00 | KDM1A (0.47) | KDM1AHTR2ASIGMAR1OPRM1GRIN2D | |
| SCHEMBL3228205 | 1.00 | KDM1A (0.47) | KDM1AHTR2ASIGMAR1OPRM1GRIN2D | |
| SCHEMBL10557026 | 1.00 | KDM1A (0.47) | KDM1AHTR2ASIGMAR1OPRM1GRIN2D | |
| SCHEMBL6230330 | 0.79 | DRD2 (0.50) | HTR2AANPEP | |
| SCHEMBL10618263 | 0.79 | MTNR1A (0.43) | KDM1AHTR2AOPRM1 | |
| SCHEMBL15018685 | 0.77 | KDM1A (0.50) | KDM1AHTR2ASIGMAR1GRIN2DGRIN3B | |
| SCHEMBL3202238 | 0.77 | KDM1A (0.50) | KDM1AHTR2ASIGMAR1GRIN2DGRIN3B | |
| SCHEMBL30968147 | 0.77 | KDM1A (0.50) | KDM1AHTR2ASIGMAR1GRIN2DGRIN3B | |
| SCHEMBL31349197 | 0.77 | KDM1A (0.50) | KDM1AHTR2ASIGMAR1GRIN2DGRIN3B | |
| SCHEMBL8068536 | 0.77 | KDM1A (0.50) | KDM1AHTR2ASIGMAR1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3506926-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | Flagship Pioneering Innovations V, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3490542-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | Flagship Pioneering Innovations V, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3490581-A2 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | Flagship Pioneering Innovations V, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| EP-3408256-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | Takeda Pharmaceutical Company Limited (JP) | 2018-12-05 | — | — | EP | disclosed |
| CN-108602760-A | Indane derivatives as MG L UR7 modulators | 武田药品工业株式会社 | 2018-09-28 | — | — | CN | disclosed |
| WO-2018047983-A1 | INDANE DERIVATIVES USEFUL AS MODULATORS OF MGLUR7 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018022666-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE | FLAGSHIP PIONEERING, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2009080223-A1 | CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
| US-20090124682-A1 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity | BIRCH ALAN MARTIN | 2009-05-14 | — | — | US | disclosed |
| US-20080293780-A1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | SANOFI-AVENTIS (FR) | 2008-11-27 | — | — | US | disclosed |
| EP-1937675-A2 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039174-A2 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2007-03-22 | — | — | US | disclosed |
| EP-1613315-A1 | QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES | Novartis AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087142-A1 | QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
| US-4861789-A | Dihydro-indene-amine-dihydrooxazoles | BEECHAM GROUP PLC (GB) | 1989-08-29 | — | — | US | disclosed |
| EP-0251453-A2 | Substituted amino-dihydrooxazoles, -thiazoles and -imidazoles, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293780-A1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PPARG, PPARA, PPARD | KDM1A 2984/4885HTR2A 1058/4885SIGMAR1 1380/4885 |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | GRM7, GRIN2B, GRM1 | KDM1A 1761/4885HTR2A 155/4885SIGMAR1 183/4885 |
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | ADRB2, ADRA2C, ADRB1 | KDM1A 2895/4885HTR2A 172/4885SIGMAR1 196/4885 |
| US-20090124682-A1 | Indan-Amide Derivatives with Glycogen Phosphorylase Inhibitory Activity | PYGL, PYGM, GYS1 | KDM1A 936/4885HTR2A 3944/4885SIGMAR1 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.